Curatio Therapeutics
- | Biotech or pharma, therapeutic R&D
- | Biotech or pharma, animal health
Curatio Therapeutics is New Haven, CT Biotech startup. Our lead asset, LMP01, is a potentially disruptive combination therapy for glioblastoma multiforme which has shown anecdotal evidence of safety, efficacy, multi-year survival and good quality of life in a small group of patients with the most aggressive forms of glioblastoma (ie:IDH 1&2 Wild Types and Unmethylated MGMT type) who initiated therapy with end-stage disease in a compassionate use setting.
Address
New HavenConnecticut
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}